S016 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session will provide an overview of national recommendations for management of cutaneous melanoma, utilizing current NCCN and AAD clinical practice guidelines. Based on the available evidence, faculty speakers will address: appropriate biopsy techniques, pathology assessment (including AJCC 8th edition staging), molecular/gene expression profiling (for biopsy, pathologic assessment and prognosis), sentinel lymph node biopsy (including risk prediction tools), surgery (including Mohs micrographic surgery and staged excision with permanent sections), topical therapy for melanoma in situ/lentigo maligna type, surveillance, and adjuvant therapy for resected stage II (primary) and stage III (node-positive) melanoma.
LEARNING OBJECTIVES
Apply current AAD and NCCN cutaneous melanoma guidelines to clinical practice.
Recognize limitations and benefits of diagnostic and prognostic testing for clinical-decision making, including histopathologic parameters, molecular testing, and SLNB risk prediction and prognosis.
Describe the role of adjuvant therapy for resected stage II and stage III melanoma, including potential risks and benefits.
SCHEDULE
6:00 PM
Introduction
Christopher K. Bichakjian, MD, FAAD
6:05 PM
Pathology Reporting & AJCC Staging
Michael Tetzlaff, MD, PhD
6:25 PM
Tools for Bedside Diagnosis of Melanoma
Caroline C. Kim, MD, FAAD
6:45 PM
Biopsy Techniques and Primary Surgery
Kelly Cha, MD, PhD, FAAD
7:05 PM
Prognostic Gene Expression Profiling
Douglas Grossman, MD, PhD, FAAD
7:25 PM
Mohs Surgery and Staged Excision
Christopher K. Bichakjian, MD, FAAD
7:45 PM
Alternative Therapies for Melanoma in Situ
Kelly C Nelson, MD, FAAD
8:05 PM
Sentinel Lymph Node Biopsy
8:25 PM
Adjuvant Therapy for Primary and Metastatic Melanoma
Hensin Tsao, MD, PhD, FAAD
8:45 PM
Panel Discussion
SPEAKERS
Christina Angeles
Christopher K. Bichakjian, MD, FAAD
Kelly Cha, MD, PhD, FAAD
Douglas Grossman, MD, PhD, FAAD
Caroline C. Kim, MD, FAAD
Kelly C Nelson, MD, FAAD
Michael Tetzlaff, MD, PhD
Hensin Tsao, MD, PhD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Christina Angeles
SkylineDx B.V. – Investigator(Grants/Research Funding);
Christopher K. Bichakjian, MD, FAAD
No financial relationships exist with ineligible companies.
Kelly Cha, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Douglas Grossman, MD, PhD, FAAD
DermTech Inc. – Investigator(Fees); OrLucent, Inc. – Advisory Board(Honoraria), Investigator(Fees); Skin Analytics – Investigator(Fees);
Caroline C. Kim, MD, FAAD
No financial relationships exist with ineligible companies.
Kelly C Nelson, MD, FAAD
No financial relationships exist with ineligible companies.
Michael Tetzlaff, MD, PhD
No financial relationships exist with ineligible companies.
Hensin Tsao, MD, PhD, FAAD
Epiphany Dermatology – Advisory Board(Honoraria), Advisory Board(Stock Options); Massachusetts General Hospital – Employee(Salary); UpToDate, Inc. – Other(Honoraria); Worldcare Clinical, LLC – Consultant (1099 relationship)(Fees);